According to the Food and Drug Administration (FDA), a body equivalent to Anvisa in the United States, medicines with phenylephrine may be removed from the American market once and for all.
The component is a decongestant nasal infection found in different medicines for allergies and colds in the USA and Brazil.
see more
Discovery suggests that humans already wore shoes 148 thousand years ago;…
Duo removed from Air Canada flight after refusing dirty seat…
However, according to a study carried out and revealed by the FDA itself, it does not have the desired effect when administered in pill form.
As announced to the public, the product with phenylephrine in tablet form does not have an impact on the problem even when administered in large quantities.
This is due to the fact that the substance does not come into direct contact with the nasal canal, therefore, it does not generate the expected result.
Research has revealed that phenylephrine medicine has fewer effects than placebo pills on patients with colds and allergic congestion.
Therefore, experts from the University of Florida asked the agency to withdraw the drugs from the market.
According to Jennifer Schwartzott, a member of the FDA panel: “The patient community demands and deserves medicines that treat their symptoms safely and effectively, and I don’t believe this one will do that”, indicating that removal from the market should be done as soon as possible. before.
(Image: disclosure)
Therefore, very soon the agency should take measures to remove phenylephrine from the composition of such drugs.
Another possible solution is to remove them from sales shelves and include new medicines that are more effective in treating these diseases.
Therefore, the FDA must work to protect the population's rights and prevent the type of medicine that has proven to be ineffective from continuing to be sold normally.
According to some published figures, the medicines that contain the component were responsible for generating sales of US$1.8 billion in 2022. The value is equivalent to approximately R$8.9 billion, the data was revealed directly by the FDA team.
Furthermore, according to the research results, these remedies have greater effects on cold and allergy symptoms when applied via sprays or drops. This indicates that they can continue to be sold, except in tablet format.